Skip to main content
Black Health logo Black Health
Glossary

Zuranolone

Also known as: Zurzuvae, brand name Zurzuvae

Medically reviewed, last updated

Zuranolone (brand name Zurzuvae) is the first oral medication approved by the FDA specifically for postpartum depression. Approved in August 2023, zuranolone is taken once daily for 14 days, in contrast to traditional SSRIs which require continuous use for months. It works by modulating GABA-A receptor activity.

The registration trials did not publish race-stratified efficacy results, which leaves an evidence gap for Black mothers who account for a disproportionate share of severe PPD. See our detailed explainer on zuranolone, PPD in Black women, and the race-data gap.

Back to glossary

Medical Disclaimer

This glossary entry is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.